Nature Cancer SCIE

國際簡稱：Nat Cancer 參考譯名：自然癌癥

主要研究方向：Medicine-Oncology 非預(yù)警期刊審稿周期：

《自然癌癥》(Nature Cancer)是一本由Springer Nature出版的以Medicine-Oncology為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。該期刊享有很高的科學(xué)聲譽(yù)，影響因子不斷增加，發(fā)行量也同樣高。

1區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
90 年發(fā)文量
23.5 IF影響因子
未開放 是否OA
12 issues per year 出版周期
English 出版語言

Nature Cancer aims to publish the most significant advances across the full spectrum of cancer research in the life, physical, applied and social sciences, spanning basic preclinical, translational and clinical work. The journal’s broad scope covers all cancer research offering new insights into cancer biology, genetics and genomics, new approaches for the development and delivery of diagnostics and therapies, and new ways of understanding the global societal impact of cancer, thus ensuring that the work published reaches the widest possible audience.

[ 查看全部 ]

投稿咨詢加急咨詢

Nature Cancer期刊信息

ISSN：2662-1347
出版語言：English
是否OA：未開放
E-ISSN：2662-1347
出版地區(qū)：ENGLAND
是否預(yù)警：否
出版商：Springer Nature
出版周期：12 issues per year
開源占比：0.145
Gold OA文章占比：28.57%
OA被引用占比：0.0323...
出版國人文章占比：0.03
出版撤稿占比：
研究類文章占比：87.78%

Nature Cancer CiteScore評價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

31.1

11.9

3.002

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q1	12 / 404	97%
大類：Medicine 小類：Cancer Research	Q1	8 / 230	96%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Nature Cancer中科院評價(jià)數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	ONCOLOGY 腫瘤學(xué)	1區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	1區(qū)	ONCOLOGY 腫瘤學(xué)	1區(qū)

Nature Cancer JCR評價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q1	11 / 322	96.7%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q1	10 / 322	97.05%

Nature Cancer歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Nature Cancer中國學(xué)者發(fā)文選摘

1、A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-kappa B signaling
Author: Altea-Manzano, Patricia; Doglioni, Ginevra; Liu, Yawen; Cuadros, Alejandro M.; Nolan, Emma; Fernandez-Garcia, Juan; Wu, Qi; Planque, Melanie; Laue, Kathrin Julia; Cidre-Aranaz, Florencia; Liu, Xiao-Zheng; Marin-Bejar, Oskar; Van Elsen, Joke; Vermeire, Ines; Broekaert, Dorien; Demeyer, Sofie; Spotbeen, Xander; Idkowiak, Jakub; Montagne, Aurelie; Demicco, Margherita; Alkan, H. Furkan; Rabas, Nick; Riera-Domingo, Carla; Richard, Francois; Geukens, Tatjana; De Schepper, Maxim; Leduc, Sophia; Hatse, Sigrid; Lambrechts, Yentl; Kay, Emily Jane; Lilla, Sergio; Alekseenko, Alisa; Geldhof, Vincent; Boeckx, Bram; de la Calle Arregui, Celia; Floris, Giuseppe; Swinnen, Johannes V.; Marine, Jean-Christophe; Lambrechts, Diether; Pelechano, Vicent; Mazzone, Massimiliano; Zanivan, Sara; Cools, Jan; Wildiers, Hans; Baud, Veronique; Gruenewald, Thomas G. P.; Ben-David, Uri; Desmedt, Christine; Malanchi, Ilaria; Fendt, Sarah-Maria

Journal: NATURE CANCER. 2023; Vol. 4, Issue 3, pp. 344-+. DOI: 10.1038/s43018-023-00513-2
2、A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors
Author: Ruiz-Saenz, Ana; Atreya, Chloe E.; Wang, Changjun; Pan, Bo; Dreyer, Courtney A.; Brunen, Diede; Prahallad, Anirudh; Munoz, Denise P.; Ramms, Dana J.; Burghi, Valeria; Spassov, Danislav S.; Fewings, Eleanor; Hwang, Yeonjoo C.; Cowdrey, Cynthia; Moelders, Christina; Schwarzer, Cecilia; Wolf, Denise M.; Hann, Byron; VandenBerg, Scott R.; Shokat, Kevan; Moasser, Mark M.; Bernards, Rene; Gutkind, J. Silvio; van 't Veer, Laura J.; Coppe, Jean-Philippe

Journal: NATURE CANCER. 2023; Vol. 4, Issue 2, pp. 240-+. DOI: 10.1038/s43018-022-00508-5
3、EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance
Author: Chibaya, Loretah; Murphy, Katherine C. C.; DeMarco, Kelly D. D.; Gopalan, Sneha; Liu, Haibo; Parikh, Chaitanya N. N.; Lopez-Diaz, Yvette; Faulkner, Melissa; Li, Junhui; Morris, John P. P.; Ho, Yu-jui; Chana, Sachliv K. K.; Simon, Janelle; Luan, Wei; Kulick, Amanda; de Stanchina, Elisa; Simin, Karl; Zhu, Lihua Julie; Fazzio, Thomas G. G.; Lowe, Scott W. W.; Ruscetti, Marcus

Journal: NATURE CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1038/s43018-023-00553-8
4、Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity
Author: Wu, Yuanzhong; Zhou, Liwen; Zou, Yezi; Zhang, Yijun; Zhang, Meifang; Xu, Liping; Zheng, Lisi; He, Wenting; Yu, Kuai; Li, Ting; Zhang, Xia; Chen, Zhenxuan; Zhang, Ruhua; Zhou, Penghui; Zhang, Nu; Zheng, Limin; Kang, Tiebang

Journal: NATURE CANCER. 2023; Vol. 4, Issue 3, pp. 382-+. DOI: 10.1038/s43018-023-00522-1
5、Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer
Author: Sun, Xiaoxiang; Tang, Huanyin; Chen, Yu; Chen, Zhixi; Hu, Zhiyi; Cui, Zhen; Tao, Yaming; Yuan, Jian; Fu, Yun; Zhuang, Zhigang; He, Qizhi; Li, Qian; Xu, Xianghong; Wan, Xiaoping; Jiang, Ying; Mao, Zhiyong

Journal: NATURE CANCER. 2023; Vol. , Issue , pp. -. DOI: 10.1038/s43018-023-00535-w